Comments
Hyderabad, Nov 14 Driven by strong growth in formulations exports, Natco Pharma has posted a manifold increase in its consolidated net profit at Rs 369 crore in the second quarter ended September 30, 2023, compared to Rs 57 crore in the corresponding quarter of the previous year.
The total revenue of the Hyderabad-based company has more than doubled at Rs 1,061 crore, as against Rs 452 crore for the same period last year, reflecting a growth of 134 per cent. “Business was strong during the quarter due to growth in formulation exports and increased sales in domestic agrochemical business,’‘ Natco said in a release on Tuesday.
NATCO Pharma faces antitrust lawsuit in the US, shares dip
The export of formulations contributed revenues of Rs 792 crore (Rs 283 cr in the year-ago period), followed by the domestic formulations business, which pooled in Rs 102 crore, while the crop health sciences segment earned Rs 56 crore in revenues in the quarter under review.
The Board of Directors has declared a second interim dividend of Rs 1.25 per equity share of Rs 2 for FY 2024, the company said.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.